Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,351.00DKK
18 Aug 2017
Change (% chg)

kr.-9.00 (-0.66%)
Prev Close
kr.1,360.00
Open
kr.1,354.00
Day's High
kr.1,358.00
Day's Low
kr.1,346.00
Volume
25,653
Avg. Vol
223,976
52-wk High
kr.1,489.00
52-wk Low
kr.970.00

Latest Key Developments (Source: Significant Developments)

BRIEF-Genmab CEO confident to close some tech deals this year
Thursday, 10 Aug 2017 01:03am EDT 

Repeats Wednesday's story without changes to text:IS IN PROGRESSING TALKS WITH SEVERAL COMPANIES ON NEW TECHNOLOGY COLLABORATIONS, CONFIDENT TO CLOSE SOME DEALS IN 2017, AND SOME IN 2018.DEALS ARE MORE COMPLICATED TO MAKE NOW THAN EARLIER AS GENMAB WANTS CO-OWNERSHIP OR THE OPTION OF CO-OWNERSHIP AND THAT IS NOT WHAT THE LARGE BIOTECH AND PHARMA COMPANIES LIKE TO HEAR.NEW DEALS ARE GOING TO BE MORE FAVOURABLE TOWARDS GENMAB IN THE FUTURE AS ITS DRUGS ARE WORKING WELL AND POTENTIAL PARTNERS ARE VERY EAGER TO GET ACCESS TO ITS TECHNOLOGIES.IS MOVING AGGRESSIVELY FORWARD TOGETHER WITH JANSSEN ON SUBCUTANEOUS FORMULATION OF DARATUMUMAB.IT IS INCREDIBLY IMPORTANT THAT GENMAB HAS REACHED AGREEMENT WITH REGULATORS ON HOW TO GET SUBCUTANEOUS FORMULATION OF DARATUMUMAB TO MARKET.STILL SEE LOT OF UNCERTAINTIES IN 2017, STILL NEED TO SEE PICK-UP IN DARZALEX SALES IN H2.  Full Article

Genmab Q2 net profit at DKK 307.3 million
Wednesday, 9 Aug 2017 11:03am EDT 

Aug 9 (Reuters) - GENMAB ::SAYS ‍REVENUE WAS DKK 1,024 MILLION IN FIRST HALF OF 2017 COMPARED TO DKK 524 MILLION IN FIRST HALF OF 2016​.‍MAINTAINS 2017 FINANCIAL GUIDANCE​.MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017 AND REITERATED ON MAY 10, 2017.Q2 REVENUE DKK ‍773.3​ MILLION (REUTERS POLL DKK 716 MILLION).Q2 NET PROFIT DKK 307.3 MILLION (REUTERS POLL DKK 400 MILLION).Q2 ADJUSTED OPERATING PROFIT DKK 536.4‍​ MILLION (REUTERS POLL DKK 469 MILLION).  Full Article

Genmab CEO confident to close some tech deals this year
Wednesday, 9 Aug 2017 10:15am EDT 

Aug 9 (Reuters) - GENMAB'S CEO JAN VAN DE WINKEL SAYS IN TELEPHONE INTERVIEW WITH REUTERS::IS IN PROGRESSING TALKS WITH SEVERAL COMPANIES ON NEW TECHNOLOGY COLLABORATIONS, CONFIDENT TO CLOSE SOME DEALS IN 2017, AND SOME IN 2018.DEALS ARE MORE COMPLICATED TO MAKE NOW THAN EARLIER AS GENMAB WANTS CO-OWNERSHIP OR THE OPTION OF CO-OWNERSHIP AND THAT IS NOT WHAT THE LARGE BIOTECH AND PHARMA COMPANIES LIKE TO HEAR.NEW DEALS ARE GOING TO BE MORE FAVOURABLE TOWARDS GENMAB IN THE FUTURE AS ITS DRUGS ARE WORKING WELL AND POTENTIAL PARTNERS ARE VERY EAGER TO GET ACCESS TO ITS TECHNOLOGIES.IS MOVING AGGRESSIVELY FORWARD TOGETHER WITH JANSSEN ON SUBCUTANEOUS FORMULATION OF DARATUMUMAB.IT IS INCREDIBLY IMPORTANT THAT GENMAB HAS REACHED AGREEMENT WITH REGULATORS ON HOW TO GET SUBCUTANEOUS FORMULATION OF DARATUMUMAB TO MARKET.STILL SEE LOT OF UNCERTAINTIES IN 2017, STILL NEED TO SEE PICK-UP IN DARZALEX SALES IN H2.  Full Article

Genmab: net sales of DARZALEX in Q2 totaled USD 299 mln
Tuesday, 18 Jul 2017 07:03am EDT 

July 18 (Reuters) - GENMAB A/S ::GENMAB ANNOUNCES NET SALES OF DARZALEX® (DARATUMUMAB) FOR SECOND QUARTER OF 2017 .NET SALES OF DARZALEX IN Q2 OF 2017 TOTALED USD 299 MILLION.GENMAB WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC..  Full Article

Genmab says U.S. FDA approves darzalex in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma
Friday, 16 Jun 2017 01:06pm EDT 

June 16 (Reuters) - Genmab A/S :Genmab announces u.s. fda approval of darzalex(daratumumab) in combination with pomalidomide and dexamethasone for relapsed or refractory multiple myeloma.Genmab - will receive milestone payments totaling $25 million from Janssen in connection with approval & first commercial sale of darzalex under newly expanded label.Genmab - approval and related milestones do not impact financial guidance issued by Genmab on May 10, 2017.  Full Article

Genmab Q1 oper profit DKK 46 million; above expectations
Wednesday, 10 May 2017 11:03am EDT 

May 10 (Reuters) - GENMAB :Q1 USD 255 MILLION IN NET SALES OF DARZALEX® (DARATUMUMAB); RESULTING IN ROYALTY INCOME OF DKK 211 MILLION.GENMAB - USD 255 MILLION IN NET SALES OF DARZALEX IN Q1.Q1 REVENUE DKK 251 MILLION (REUTERS POLL DKK 263 MILLION).GENMAB - IS MAINTAINING ITS 2017 FINANCIAL GUIDANCE PUBLISHED ON FEBRUARY 22, 2017..Q1 OPERATING PROFIT DKK 46 MILLION (REUTERS POLL DKK 24.7 MILLION).  Full Article

Genmab announces new late stage combination study of Daratumumab in multiple myeloma
Friday, 28 Apr 2017 09:26am EDT 

April 28 (Reuters) - Genmab A/S ::Genmab announces new phase III combination study of Daratumumab in multiple myeloma.Study is expected to start in Q2 2017 and is designed to confirm results from MMY1001 study.Prescription drug user fee act date of June 17, 2017 for Daratumumab.Janssen Research with European myeloma network plans to start phase III study of Daratumumab in relapsed and refractory multiple myeloma.  Full Article

Genmab announces European Marketing Authorization for Darzalex
Friday, 28 Apr 2017 06:26am EDT 

April 28 (Reuters) - GENMAB :GENMAB ANNOUNCES EUROPEAN MARKETING AUTHORIZATION FOR DARZALEX® (DARATUMUMAB) FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA.SAYS GENMAB WILL RECEIVE MILESTONE PAYMENTS TOTALING USD 48 MILLION FROM JANSSEN BIOTECH, INC.SAYS THESE MILESTONE PAYMENTS WERE INCLUDED IN FINANCIAL GUIDANCE ISSUED BY GENMAB ON FEBRUARY 22, 2017 AND THEREFORE THERE IS NO CHANGE TO COMPANY'S FINANCIAL GUIDANCE FOLLOWING THIS APPROVAL.  Full Article

Genmab Q1 net sales of Darzalex at $255 million
Tuesday, 18 Apr 2017 06:55am EDT 

April 18 (Reuters) - GENMAB A/S GEN.CO:GENMAB ANNOUNCES NET SALES OF DARZALEX®(DARATUMUMAB) FOR FIRST QUARTER OF 2017<<>>.NET SALES OF DARZALEX IN Q1 OF 2017 TOTALED $255 MILLION.SAYS WILL RECEIVE ROYALTIES ON WORLDWIDE NET SALES FROM JANSSEN BIOTECH, INC.  Full Article

BRIEF-Genmab A/S says Phase II study in NHL will not proceed
Friday, 31 Mar 2017 02:02am EDT 

Genmab A/S : Phase II study of daratumumab in Non-Hodgkin’S Lymphoma will not proceed to stage 2 of trial . Genmab says Phase II study (CARINA, LYM2001) in NHL will not proceed . Genmab says other ongoing and planned studies with daratumumab in lymphomas and other cancers outside multiple myeloma continue as planned . Genmab says announcement has no impact on other ongoing or planned studies with daratumumab . Collaboration partner for daratumumab, Janssen Biotech, has decided not to initiate stage 2 of Phase II study (CARINA, LYM2001) of daratumumab . Study will not proceed to stage 2 based on results of a data review . Review showed 2 cohorts investigating use of daratumumab monotherapy in relapsed patients with FL, DLBCL didn't reach predefined ORR futility thresholds .In third cohort in study, patients with mantle cell lymphoma (MCL), ORR was not evaluable due to slow recruitment.  Full Article

RPT-BRIEF-Genmab CEO confident to close some tech deals this year

Aug 9 GENMAB'S CEO JAN VAN DE WINKEL SAYS IN TELEPHONE INTERVIEW WITH REUTERS: